Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company

Haisco Pharmaceutical Group Registers Delaware Subsidiary to Expand Global Operations

Fineline Cube Feb 10, 2025

Shenzhen-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the registration of a new...

Company Drug

Beijing Luzhu Submits BLA for LZ901 Herpes Zoster Vaccine to NMPA

Fineline Cube Feb 10, 2025

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a human vaccine and therapeutic biologics manufacturer, announced...

Company Drug Hospital

Hainan Boao Lecheng Pilot Zone Implements Baclofen Intrathecal Therapy

Fineline Cube Feb 10, 2025

The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica,...

Company Deals

Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs

Fineline Cube Feb 10, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in...

Policy / Regulatory

NMPA’s New Guidelines for Drug Registration Review

Fineline Cube Feb 10, 2025

A Look at the New Rules for Chemical and Biological Drug Filings in China:The Center...

Policy / Regulatory

Shanghai’s Three-Year Plan to Boost Elderly Care Quality

Fineline Cube Feb 10, 2025

A Comprehensive Look at Shanghai’s Efforts to Integrate Medical Care and Elderly Care:The Shanghai Civil...

Company Drug

NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer

Fineline Cube Feb 10, 2025

The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...

Policy / Regulatory

Tianjin Municipality Boosts Biopharmaceutical Industry with New Measures

Fineline Cube Feb 10, 2025

An In – Depth Look at Tianjin’s Efforts to Accelerate Medical Innovation and Gather Resources:The...

Company Drug

Hansoh Pharma’s Uplizna Receives Priority Review for IgG4-RD Treatment

Fineline Cube Feb 10, 2025

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

NMPA Seeks Public Feedback on Export Drug Manufacturing Rules

Fineline Cube Feb 10, 2025

An In – Depth Look at the New Draft Proposal for the Administration and Management...

Company Deals

VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally

Fineline Cube Feb 10, 2025

China-based gene delivery technology developer VectorBuilder has formed a strategic alliance with compatriot firm Shenzhen...

Policy / Regulatory

China’s Drug Procurement Under Scrutiny: Addressing Quality Concerns and Policy Reforms

Fineline Cube Feb 10, 2025

An In – Depth Exploration of the Recent Survey on Bulk Drug Procurement in China...

Policy / Regulatory

In-Depth Analysis of NHSA’s DRG/DIP Payment Reforms: A Path to Streamlined Healthcare Management

Fineline Cube Feb 10, 2025

Comprehensive Overhaul of Payment SystemsThe National Healthcare Security Administration (NHSA) has unveiled a series of...

Company Drug

CSPC Pharmaceutical’s mRNA Vaccine SYS6017 Gains NMPA Approval for Herpes Zoster Study

Fineline Cube Feb 8, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...

Company Drug

Nuance Pharma’s Ohtuvayre Receives Regulatory Approval in Macau for COPD Treatment

Fineline Cube Feb 8, 2025

China-based Nuance Pharma announced that it has received regulatory approval in Macau for its Ohtuvayre...

Company

Regend Therapeutics’ Pulmovinci Receives FDA Orphan Drug Designation for IPF

Fineline Cube Feb 8, 2025

Suzhou-based stem cell therapy specialist Regend Therapeutics announced that the US Food and Drug Administration...

Company Drug

Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment

Fineline Cube Feb 8, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval...

Company Drug

CanSino Biologics’ DTcP Vaccine for Infants Gains Priority Review in China

Fineline Cube Feb 8, 2025

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) announced that the New Drug Application (NDA)...

Company Drug

Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis

Fineline Cube Feb 8, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received another indication approval from...

Company Drug

Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference

Fineline Cube Feb 8, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study,...

Posts pagination

1 … 255 256 257 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.